Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $84.12, for a total transaction of $239,742.00. Following the transaction, the chief financial officer owned 177,543 shares of the company’s stock, valued at $14,934,917.16. This represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $83.05 on Thursday. The business’s 50-day moving average is $80.77 and its two-hundred day moving average is $79.35. The company has a market capitalization of $1.89 billion, a P/E ratio of 21.03 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.60 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the business posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Pacer Advisors Inc. grew its holdings in ANI Pharmaceuticals by 6.9% in the first quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock valued at $6,572,000 after purchasing an additional 5,548 shares during the period. Bank of America Corp DE raised its stake in shares of ANI Pharmaceuticals by 229.4% during the 1st quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock worth $11,576,000 after buying an additional 104,828 shares during the period. Janus Henderson Group PLC raised its stake in shares of ANI Pharmaceuticals by 1,308.1% during the 1st quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock worth $8,425,000 after buying an additional 101,772 shares during the period. California State Teachers Retirement System lifted its position in shares of ANI Pharmaceuticals by 57.3% during the 1st quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after buying an additional 8,946 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 143 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

ANIP has been the subject of a number of analyst reports. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.